CRBU CRBU
Company Profile ↓Company Overview
CRBU (CRBU) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 11.6% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.26.
Recent Developments
- Dec 2025 Revenue of $11.16M (+11.7% YoY); net profit $-148.12M.
- Trailing 12 Months Year-on-year growth — revenue +11.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 11.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 11.56% |
| 1 Year: | 11.66% |
Stock Price Performance
| 1 Year: | -23.33% |
| 6 Months: | +3.21% |
| 3 Months: | -16.58% |
| 1 Month: | -16.15% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.66 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 11.6% over 5 years.
CONS
- Trading 43.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.70M | 8.48M | 1.20M | 984.00K | 1.59M | 1.48M | 3.98M | 2.56M | 2.66M | 4.19M | 3.30M | 3.50M | 3.75M | 23.66M | 2.43M | 3.46M | 2.02M | 2.35M | 2.67M | 2.20M | 2.40M |
| Operating Income | -10.43M | -2.25M | -8.23M | -15.21M | -13.18M | -15.96M | -18.62M | -20.41M | -20.85M | -28.43M | -26.54M | -31.12M | -32.87M | -14.63M | -46.00M | -43.50M | -38.24M | -42.91M | -47.58M | -29.40M | -26.28M |
| Net Income | -9.80M | -1.87M | -7.93M | -14.70M | -13.16M | -14.31M | -20.97M | -18.48M | -19.09M | -26.70M | -26.65M | -28.04M | -29.52M | -10.00M | -41.23M | -37.70M | -34.68M | -39.99M | -54.10M | -27.55M | -25.09M |
| Diluted EPS | - | - | - | - | - | -1.39 | -0.46 | - | -0.32 | -0.44 | -0.44 | -0.46 | -0.48 | -0.12 | -0.46 | -0.42 | -0.38 | -0.43 | -0.58 | -0.30 | -0.26 |
| R&D Expense | 8.64M | 7.58M | 6.18M | 12.02M | 10.16M | 12.33M | 15.83M | 15.11M | 13.92M | 22.58M | 19.99M | 25.71M | 26.50M | 28.58M | 33.79M | 35.48M | 30.42M | 35.53M | 27.69M | 22.40M | 20.61M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 5.79M | 12.36M | 9.60M | 13.85M | 34.48M | 9.99M | 11.16M |
| Operating Income | -34.30M | -36.12M | -66.98M | -106.40M | -116.06M | -166.62M | -148.34M |
| Net Income | -23.43M | -34.31M | -66.92M | -99.42M | -102.07M | -149.10M | -148.12M |
| Diluted EPS | - | - | -2.11 | -1.64 | -1.38 | -1.65 | -1.59 |
| R&D Expense | 23.64M | 34.42M | 52.26M | 82.23M | 112.08M | 130.15M | 109.44M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 36.05M | 442.36M | 373.76M | 432.21M | 313.31M | 175.37M |
| Total Equity | 29.95M | 7.46M | -23.44M | 387.82M | 300.87M | 368.40M | 252.95M | 122.17M |
| Cash & Equivalents | - | 41.07M | 15.95M | 240.42M | 58.34M | 51.16M | 16.29M | 12.36M |
| Total Liabilities | - | - | 18.16M | 54.53M | 72.89M | 63.81M | 60.36M | 53.19M |
| Current Liabilities | - | - | 12.39M | 25.83M | 28.13M | 28.30M | 30.65M | 25.41M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -32.01M | -33.22M | -32.52M | -90.97M | -93.29M | -138.20M | -110.99M |
| Investing Cash Flow | 27.23M | 6.36M | -176.40M | -93.25M | -68.18M | 86.61M | 102.24M |
| Financing Cash Flow | 172.00K | 1.74M | 433.43M | 2.13M | 154.30M | 16.72M | 4.82M |
| Capital Expenditure | -884.00K | -317.00K | -2.12M | -6.45M | -11.61M | -4.88M | -1.36M |
| Free Cash Flow | -32.89M | -33.53M | -34.64M | -97.42M | -104.90M | -143.08M | -112.35M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | -592.7% | -292.2% | -697.8% | -768.2% | -336.6% | -1,667.2% | -1,329.4% |
| Net Margin % | -404.8% | -277.6% | -697.3% | -717.8% | -296.1% | -1,491.9% | -1,327.4% |
| ROE % | -314.0% | 146.4% | -17.3% | -33.0% | -27.7% | -58.9% | -121.2% |
| ROCE % | - | -152.7% | -16.1% | -30.8% | -28.7% | -58.9% | -98.9% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CRBU
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxONXJDUllyVkQ0RlBmRGhJVGtWWl9wbGZvRVhkV2RJbTRBN1l3M2hFNVhyamhhLW9KN1dFX0ktY2JlTzhHS1FOWkp3OUJCVDY2U0VoSU1uTEdlbTZZUnF0WWlsbzRzaUh6RENGMkNwa0dha1JJeENwb0xycEhzdWZ1eDBicDQ2WnBuTVF3ZF…
Price to sales forward of Caribou Biosciences, Inc. – NASDAQ:CRBU - TradingView
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPbGFvcTZ4NXNqalRXRXpzYUwtaUw0LVNRSUR4Wjk5M1Q3VFgxbE9DdHpHdV9zWEY4YjRJWnhuRHgxOVpUWkVEdGNYTzh1aW1IenljbmQxQk9MWXVKNm9mMFoya3NUNTVmOHlVWmNQdkJUSDZhTUF0N0VNWjNid2M2OWFFc3R5OWl5WDROY0…
$CRBU stock is down 14% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQM1d4NXZNR2NmT01vMXJYekRIYXl1QnZaS21obXpid3pDSHQ1VVp0Znl0YkJEWjNjVWY0TVVRVVNuNHJoVTNqeE1wWnBYOGRtM0Rsc2xjQlhxOUV2WWItaklKdHlxdXRDSXZ5NnNyUkFtWjlsMzZscGZnc1h6UHUtdVJvNzlGRzM4bFVaNE…
Caribou CEO set for fireside chat at cell therapy conference June 30 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPQ1djN1NnVTkwZUhvSW5rbWhNQkd6ZzQ5VHNvSEwxUDNDZnZZZzhzYXlzYWlhQ1dKWG9WTkpxM1JkVVdFdUE2Q1JTY1ZtbmVGZFFXbnllbjBQUDJpejBRSk1DOExDaHJKdjRwNkh0OWRfdHhyaGktVGNEQjNJTWFXcWw0aGtiaDFQRng5N0…
H.C. Wainwright reiterates Caribou Biosciences stock rating at buy - Investing.com
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxONTk2b2hkMm9xY0p4dmw5eXU4T2dsVi11d2hVVWlnTkNlaTk2Nm1LQktORlIzaDlUYU9hUFA0ZUROajBrTUl1S0NMYUtxeVQ5anFFVFUtbDlNUm5iZ1kxbnQ4YW1fcTk3blNrSWt2QUthaFlkdkdsTW1SLS1wQ0FlTnA3NWNYbHlPbVR5NH…
CRBU|Caribou Biosciences Inc|Price:1.460|Chg%:-0.000 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE15bFpKaWVTaG5wNjdJLThLc3lPUWZ1MGpVNTVTVGNiR3ZNTmtIX2JnbndXS0ExRi1mTGV3bHpVNkk1ZTZqY3RobkNUbl9fb0EyeDZpdC1ra1ZLVXVNeldrd2xhTDl4dl9sbkRuMkxR?oc=5" target="_blank">CRBU|Caribou Biosci…
CRBU — Frequently Asked Questions
What is the current share price of CRBU?
As of 2026-08-05 17:25 PDT, CRBU trades at $1.61 on NASDAQ/NYSE. Its 52-week range is $1.39 to $2.84.
What is the P/E ratio of CRBU?
CRBU trades at a trailing price-to-earnings (P/E) ratio of -1.01.
What is the return on equity (ROE) of CRBU?
CRBU has a return on equity (ROE) of -121.24%. Its return on capital employed (ROCE) is -98.93%.
Is CRBU a good stock to buy?
This page provides a data-driven analysis of CRBU, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.